AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT03682497
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)
Completed
- Conditions
- Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53940
- Registration Number
- NCT03657875
- Locations
- 🇷🇺
Invitro, Moscow, Russian Federation
To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03658213
- Locations
- 🇨🇳
Research Site, Tianjin, China
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
Completed
- Conditions
- StrokeCardiovascular DeathHeart Attack
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1576
- Registration Number
- NCT03654157
- Locations
- 🇷🇺
Research Site, Moscow, Moscow/Russia, Russian Federation
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
Phase 1
Completed
- Conditions
- Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)Healthy Participants
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT03649165
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT03645434
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: MEDI0382 100 μgDrug: PlaceboADrug: PlaceboBDrug: MEDI0382 50 ugDrug: MEDI0382 200 μgDrug: MEDI0382 300 μg
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT03645421
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
The Study for Evaluating Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients With COPD.
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 505
- Registration Number
- NCT03642613
- Locations
- 🇯🇵
Tohoku University School of Medicine, Sendai, Miyagi, Japan
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 634
- Registration Number
- NCT03643484
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
Completed
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5067
- Registration Number
- NCT03633838
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath